The optimal anticoagulation strategy for COVID-19, prophylactic or therapeutic?: a meta-analysis, trial sequential analysis, and meta-regression of more than 27,000 participants

BACKGROUND: Anticoagulants are promising regimens for treating coronavirus disease 2019 (COVID-19). However, whether prophylactic or intermediate-to-therapeutic dosage is optimal remains under active discussion. METHODS: We comprehensively searched PubMed, Embase, Scopus, Web of Science, Cochrane Li...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Mingyue, Han, Qi, Xing, Jiaxuan, Xu, Feng, Wang, Jiali, Li, Chuanbao, Shan, Zechen, Bian, Yuan, Wang, Hao, Xue, Li, Yuan, Qiuhuan, Pan, Chang, De, Yanshan, Wang, Xingfang, Hao, Panpan, Cao, Shengchuan, Pang, Jiaojiao, Chen, Yuguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555559/
https://www.ncbi.nlm.nih.gov/pubmed/37521812
http://dx.doi.org/10.1097/EC9.0000000000000059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555559/
https://www.ncbi.nlm.nih.gov/pubmed/37521812
http://dx.doi.org/10.1097/EC9.0000000000000059

Ejemplares similares